Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-3: Mevrometostat plus enzalutamide in metastatic castration-sensitive prostate cancer
jRCT2031250368Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Mevrometostat + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS). Started Oct 2025; status: recruiting.
02
Drugs
mevrometostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250368.